Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance

TACTILE SYSTEMS TECHNOLOGY INC

2025-Q1 EPS reported -$0.13 revenue$61,268,000

Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.
Adjusted EBITDA loss $0.3M vs positive $1.0M in prior-year quarter.
Lymphedema product sales -3% YoY; airway clearance +22% YoY.
FY 2025 revenue guidance lowered to $309-315M (prior $316-322M); EBITDA guidance cut to $32-34M from $35-37M.
Repurchased $10M of stock in Q1; $16.5M remaining under $30M buyback program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.